Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 3/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26126544 | 0.96 | JAK3 (0.49) | JAK3GRIN2BGRIN2CHPGDUSP2 | |
| SCHEMBL2981422 | 0.95 | JAK3 (0.48) | JAK3GRIN2BGRIN2CHPGDUSP2 | |
| SCHEMBL14669188 | 0.95 | JAK3 (0.45) | JAK3GRIN2BGRIN2CHPGDUSP2 | |
| SCHEMBL29584537 | 0.93 | JAK3 (0.47) | JAK3GRIN2BGRIN2CHPGDUSP2 | |
| SCHEMBL18389862 | 0.88 | JAK3 (0.42) | JAK3GRIN2BGRIN2CHPGDUSP2 | |
| SCHEMBL27374605 | 0.87 | JAK3 (0.43) | JAK3GRIN2BGRIN2CHPGDUSP2 | |
| SCHEMBL24308904 | 0.87 | JAK3 (0.42) | JAK3GRIN2BGRIN2CHPGDUSP2 | |
| SCHEMBL22642330 | 0.87 | JAK3 (0.42) | JAK3GRIN2BGRIN2CHPGDUSP2 | |
| SCHEMBL700241 | 0.87 | JAK3 (0.43) | JAK3GRIN2BGRIN2CHPGDUSP2 | |
| SCHEMBL31078757 | 0.87 | CHRM2 (0.44) | JAK3GRIN2BGRIN2CHPGDUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130131041-A1 | SPIROCYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8349825-B2 | Spirocyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | MERCK & CO., INC (US) | 2011-04-28 | — | — | US | disclosed |
| EP-0942731-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SUBSTANCE USE DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| EP-0942728-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEXUAL DYSFUNCTION | MERCK SHARP & DOHME LTD. (GB) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998024444-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SUBSTANCE USE DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998024442-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING SEXUAL DYSFUNCTION | MERCK SHARP & DOHME LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098268-A1 | SPIROCYCLIC COMPOUNDS | BRDT, TXNRD3, HDAC1 | JAK3 3428/4885GRIN2B 2213/4885GRIN2C 1385/4885 |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | CDK4, CDKL4, CDK2 | JAK3 337/4885GRIN2B 3381/4885GRIN2C 2487/4885 |
| US-20130131041-A1 | SPIROCYCLIC COMPOUNDS | BRDT, TXNRD3, HDAC1 | JAK3 3428/4885GRIN2B 2213/4885GRIN2C 1385/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | JAK3 337/4885GRIN2B 3381/4885GRIN2C 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.